Nephros Appoints Dan D'Agostino as CFO and Reports Third Quarter Financial Results Finance Veteran Strengthens Management Team; Quarter-over-Quarter Net Revenue up 34%; Year-over-Year down 31%

Appoints Dan D'Agostino as CFO

Reports Third Quarter Financial Results

Veteran Strengthens Management Team;

Quarter-over-Quarter

Net Revenue up 34%; Year-over-Year down 31%

ORANGE, NJ, November 5, 2020 - Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells high

performance water purification products and pathogen detection systems to the medical and commercial markets, today announced

that Dan D'Agostino was appointed the company's Chief Financial Officer, effective November 6, 2020. Nephros also

announced financial results for the three months ended September 30, 2020.

have known Dan for years, and are very pleased to announce his addition to the team," said Andy Astor, Chief Executive Officer

of Nephros. "Dan brings deep experience and knowledge of the microcap life sciences environment, having served as CFO in

a microcap firm and in other senior roles at several investment banks. Dan also provided financial advice to Nephros during the

2018 capital raise for our subsidiary, Specialty Renal Products ("SRP")."

have been impressed with Nephros's turnaround over the past few years and am excited to join the team," said Dan D'Agostino.

"With nearly four years of continuous revenue growth prior to the COVID-19 pandemic, I believe Nephros is strongly positioned

to return to high growth rates in 2021, and I look forward to help drive the company forward."

D'Agostino brings 30 years of financial leadership to Nephros, with experience at firms including Synergy Pharmaceuticals,

where he served as CFO, as well as R.W. Pressprich, AmeriTech Advisors, ThinkEquity, Punk Ziegel, Gerard Klauer Mattison, Deutsche

Bank, and Wasserstein Perella.

Filtration Business Segment Highlights

are pleased that third quarter performance was significantly stronger than the second quarter, with sequential growth at 34%,"

said Mr. Astor. "While our year-over-year revenues declined due to the COVID-19 pandemic, our recurring revenues remained

strong, in spite of interruptions in new customer acquisitions and in emergency response revenues. We continue to believe that

strong recurring revenues and high customer retention rates are two of the best indicators of the underlying strength of our business."

Astor continued, "During the remainder of 2020, we will stay focused on expanding our commercial filtration business, further

productizing our pathogen detection products, including PluraPath , DialyPath , and SequaPath , and assisting

SRP in submitting its second-generation HDF product for FDA clearance."

Financial Performance for the Quarter Ended September 30, 2020

revenue for the quarter ended September 30, 2020 was $2.1 million, compared with $3.1 million in 2019, a decrease of 31%.

loss for the quarter ended September 30, 2020 was $1.0 million, compared with a net loss of $0.7 million in 2019 an increase of

EBITDA for the quarter ended September 30, 2020 was ($1.0 million), compared with ($0.2 million) in 2019.

of goods sold for the quarter ended September 30, 2020 was $0.9 million, compared with $1.3 million in 2019, a decrease of 30%.

Gross margins for the quarter ended September 30, 2020 were 58%, compared with 59% in 2019. Management expects future gross margins

to continue in the range of 55% to 60%.

and development expenses for the quarter ended September 30, 2020 were $0.75 million, compared with $0.78 million in 2019, a decrease

and amortization expenses for the quarter ended September 30, 2020 were approximately $49,000, compared with approximately $44,000

in 2019, an increase of 11%.

general and administrative expenses for the quarter ended September 30, 2020 were $1.5 million, compared with $1.8 million in

2019, a decrease of 14%.

of September 30, 2020, Nephros had cash and cash equivalents of $5.2 million. On October 16, Nephros raised an additional $5 million

from existing shareholders at $6.00 per share.

EBITDA Definition and Reconciliation to GAAP Financial Measures

EBITDA is calculated by taking net (loss) income calculated in accordance with generally accepted accounting principles ("GAAP")

and excluding all interest-related expenses and income, tax-related expenses and income, non-recurring expenses and income, and

non-cash items, including depreciation and amortization and non-cash compensation. The following table presents a reconciliation

of Adjusted EBITDA to net (loss) income, the most directly comparable GAAP financial measure, for the third quarter of the 2020

and 2019 fiscal years for both Nephros (on a consolidated basis) and the Water Filtration Business Segment:

believes that Adjusted EBITDA provides useful information to management and investors regarding certain financial and business

trends relating to Nephros's financial condition and results of operations. Management does not consider Adjusted EBITDA

in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted

EBITDA is that it excludes significant expenses and income that are required by GAAP to be recognized in Nephros's consolidated

financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments

by management about which expenses and income are excluded or included in determining Adjusted EBITDA. In order to compensate

for these limitations, management presents Adjusted EBITDA in connection with net (loss) income, the most directly comparable

GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted EBITDA to net (loss) income and not to

rely on any single financial measure to evaluate the business.

Call Today at 4:30 p.m. ET

will host a conference call today at 4:30 PM Eastern Time, during which management will discuss Nephros's financial results

and provide a general business overview.

may dial into the following number to access the call: 1-844-808-7106.

International callers may use 1-412-317-5285.

Please ask to be joined into the Nephros conference call. A replay of the call can be accessed until November 12, 2020 at 1-877-344-7529

or 1-412-317-0088 for international callers and entering replay

access code: 10144285. An audio

archive of the call will be available shortly after the call on the Nephros investor relations page at https://investors.nephros.com/events/.

is a commercial-stage company that develops and markets high-performance water purification products and pathogen detection systems

for medical and commercial markets.

ultrafilters are used in hospitals, medical clinics, and commercial facilities to retain bacteria and viruses from water, providing

barriers that aid in infection control for showers, sinks, and ice machines. Nephros ultrafilters are also used in dialysis centers

to aid in the removal of endotoxins and other biological contaminants from water and bicarbonate concentrate in hemodialysis machines.

pathogen detection systems, including the PluraPath and SequaPath systems, provide near-real time information on bacterial genera,

waterborne bacteria, and viruses to medical and water safety professionals. These products integrate Nephros ultrafilters with

DNA sequencing and quantitative polymerase chain reaction (qPCR) technology.

commercial filters, including AETHER brand filters, improve the taste and odor of water, and reduce scale build-up in downstream

equipment. Nephros and AETHER products are used in the health care, food service, hospitality, and convenience store markets.

more information about Nephros, please visit its website at www.nephros.com.

release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements

regarding expected growth rates, expansion in our commercial filtration business, the expected development of our pathogen detection

products, the timing for SRP's submission of the second-generation HDF device for FDA clearance, management's expectations

regarding future gross margins, and other statements that are not historical facts, including statements which may be accompanied

by the words "intends," "may," "will," "plans," "expects," "anticipates,"

"projects," "predicts," "estimates," "aims," "believes," "hopes,"

"potential" or similar words. Actual results could differ materially from those described in these forward-looking

statements due to certain factors, including the impact of Covid-19, uncertainty in clinical outcomes, potential delays in the

regulatory approval process, changes in business, economic and competitive conditions, the availability of capital when needed,

dependence on third-party manufacturers and researchers, regulatory reforms, uncertainties in litigation or investigative proceedings,

and the availability of financing. These and other risks and uncertainties are detailed in Nephros's reports filed with

the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019. Nephros

does not undertake any responsibility to update the forward-looking statements in this release.

INC. AND SUBSIDIARIES

thousands, except share amounts)

INC. AND SUBSIDIARIES

OF OPERATIONS AND COMPREHENSIVE LOSS

thousands, except share amounts)